HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goss, C. H Articles by Burns, J. L Search for Related Content PubMed PubMed Citation Articles by Goss, C. H Articles by Burns, J. L Topic Collections Relevant Articles

Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis

¹ Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
² Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA

Correspondence to:
Correspondence to:
Dr Christopher H Goss
Department of Medicine, University of Washington Medical Center, Campus Box 356522, 1959 NE Pacific, Seattle, Washington 98195, USA; goss{at}u.washington.edu

With the improving survival of patients with cystic fibrosis (CF), the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the course, prognosis and complications of the disease. This review provides a summary of the pathophysiology, clinical epidemiology and microbial epidemiology of a CF pulmonary exacerbation.

Abbreviations: ARIC, Acute Respiratory Illness Checklist; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane regulator; FEV₁, forced expiratory volume in 1 s; IL, interleukin; MCBT, multiple combination bactericidal testing; RSSQ, Respiratory and Systemic Symptoms Questionnaire; TNF, tumour necrosis factor

Relevant Articles

Airwaves

Wisia Wedzicha
Thorax 2007 62: 281a. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				B. E. van Ewijk, M. M. van der Zalm, T. F. W. Wolfs, A. Fleer, J. L. L. Kimpen, B. Wilbrink, and C. K. van der Ent Prevalence and Impact of Respiratory Viral Infections in Young Children With Cystic Fibrosis: Prospective Cohort Study Pediatrics, December 1, 2008; 122(6): 1171 - 1176. [Abstract] [Full Text] [PDF]

				C. J. Blohmke, R. E. Victor, A. F. Hirschfeld, I. M. Elias, D. G. Hancock, C. R. Lane, A. G. F. Davidson, P. G. Wilcox, K. D. Smith, J. Overhage, et al. Innate Immunity Mediated by TLR5 as a Novel Antiinflammatory Target for Cystic Fibrosis Lung Disease J. Immunol., June 1, 2008; 180(11): 7764 - 7773. [Abstract] [Full Text] [PDF]

				M. M. Tunney, T. R. Field, T. F. Moriarty, S. Patrick, G. Doering, M. S. Muhlebach, M. C. Wolfgang, R. Boucher, D. F. Gilpin, A. McDowell, et al. Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 995 - 1001. [Abstract] [Full Text] [PDF]

				N. A. Jarad and K. Giles Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis Chronic Respiratory Disease, February 1, 2008; 5(1): 29 - 33. [Abstract] [PDF]

				B. W. Ramsey Outcome Measures for Development of New Therapies in Cystic Fibrosis: Are We Making Progress and What Are the Next Steps? Proceedings of the ATS, August 1, 2007; 4(4): 367 - 369. [Full Text] [PDF]

				S. C Bell and P. J Robinson Exacerbations in cystic fibrosis: 2 {middle dot} Prevention Thorax, August 1, 2007; 62(8): 723 - 732. [Abstract] [Full Text] [PDF]

				J S Elborn and S C Bell Pulmonary exacerbations in cystic fibrosis and bronchiectasis Thorax, April 1, 2007; 62(4): 288 - 290. [Full Text] [PDF]